Plus Therapeutics announced its financial results for the first quarter ended March 31, 2025, on May 30, 2025. The company reported a net loss of $17.40 million for the quarter.
As of March 31, 2025, the company held $9.87 million in cash and cash equivalents and $3.53 million in investments, totaling $13.40 million in liquid assets. Operating expenses for Q1 2025 were $4.60 million, a decrease from $4.98 million in Q1 2024.
Net cash used in operating activities during the first quarter of 2025 was $6.17 million. The company stated that its cash position improved due to a recent financing and ongoing grant support.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.